Amberstone Biosciences
PrivateLast Round
Series A
Jan 3, 2022
Total Funding Raised
$12.23M
Company Overview
Amberstone Biosciences operates in Healthcare & Life Sciences and is based in Irvine, California. Its latest recorded funding round was a Series A round in January 2022.
Amberstone Biosciences is a biotechnology company developing a novel class of targeted and conditionally active immunotherapeutics to treat solid tumor cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Amberstone Biosciences Comparables
Compare Amberstone Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bonum Therapeutics | 89% | |
| Revitope Oncology, Inc. | 85% | |
| Tentarix Biotherapeutics | 82% |
For institutional investors. Book with your work email.
Amberstone Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jan 3, 2022 | ||||
| Grant | Aug 29, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Amberstone Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Co-Win Ventures | Series A |
| Viva BioInnovator | Series A |
| Sinovation Ventures | Series A |
| National Science Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 19, 2026
Monthly visitors grew 461% MoM, from 285 to 1.6K.
- Nov 7, 2025
Monthly visitors grew 61% MoM, from 664 to 1.1K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 25, 2026
Amberstonebio develops conditionally activated T-cell engagers against up to two tumor-associated antigens for solid tumors with Henlius under a $440M collaboration and license agreement.
- is_developingSep 25, 2026
Amberstonebio agrees to develop conditionally activated solid-tumour T-cell engager candidates with Shanghai Henlius Biotech under a partnership and licence agreement to treat solid tumours on Sep 25th '26.
- is_developingSep 25, 2026
Amberstonebio is developing pH-gated, tumour-activated T-cell engagers and other antibody therapeutics through internal programmes and partnerships, with its lead T-MATE engager in IND-enabling development and expected to enter clinical development in H1 '27.
- licenses_technologySep 24, 2026
On Sep 24th '26 in California, Amberstonebio licenses its T-MATE platform technology to Henlius to generate preclinical candidates against up to two targets, with Henlius leading subsequent research, development, manufacturing, and commercialization worldwide.
For institutional investors. Book with your work email.
Amberstone Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Amberstone Biosciences's valuation, stock price, and market status.
Is Amberstone Biosciences a public or private company?
Amberstone Biosciences is a private company.
What is the current stock price of Amberstone Biosciences?
Amberstone Biosciences is a private company, so its shares have no public market price. Caplight tracks Amberstone Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Amberstone Biosciences worth (valuation)?
Valuation information for Amberstone Biosciences is not publicly available.
Can I buy Amberstone Biosciences stock?
Amberstone Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Amberstone Biosciences's last funding round?
Amberstone Biosciences's most recent funding round was Series A on January 3, 2022.
Who are the main investors in Amberstone Biosciences?
Key investors in Amberstone Biosciences include Co-Win Ventures, Viva BioInnovator, Sinovation Ventures.
Will Amberstone Biosciences IPO soon?
No public IPO plans have been announced for Amberstone Biosciences.
How can I track Amberstone Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Amberstone Biosciences's shares on secondary markets.